NasdaqCM - Nasdaq Real Time Price • USD
Cidara Therapeutics, Inc. (CDTX)
As of 11:38 AM EDT. Market Open.
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 1 | 1 | 2 | 2 |
| Avg. Estimate | -1.4 | -4 | -13.5 | 0.1 |
| Low Estimate | -1.4 | -4 | -14 | -12.4 |
| High Estimate | -1.4 | -4 | -13 | 12.6 |
| Year Ago EPS | 0.6 | -2.8 | -5.2 | -13.5 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 2 | 2 | 3 | 3 |
| Avg. Estimate | 12.9M | 5.7M | 24.34M | 45.96M |
| Low Estimate | 11.3M | 3.3M | 5.8M | 9.3M |
| High Estimate | 14.5M | 8.1M | 39.3M | 107.17M |
| Year Ago Sales | 25.99M | -- | 63.91M | 24.34M |
| Sales Growth (year/est) | -50.40% | -- | -61.90% | 88.80% |
Earnings History
| CURRENCY IN USD | 3/31/2023 | 6/30/2023 | 9/30/2023 | 12/31/2023 |
|---|---|---|---|---|
| EPS Est. | -0.73 | -2.6 | -3.25 | -2.07 |
| EPS Actual | 0.6 | -2.8 | -1.8 | -0.8 |
| Difference | 1.33 | -0.2 | 1.45 | 1.27 |
| Surprise % | 182.20% | -7.70% | 44.60% | 61.40% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | -1.4 | -4 | -13.5 | 0.1 |
| 7 Days Ago | -0.06 | -0.13 | -0.58 | -0.13 |
| 30 Days Ago | -0.06 | -0.13 | -0.58 | -0.13 |
| 60 Days Ago | -0.06 | -0.13 | -0.58 | -0.13 |
| 90 Days Ago | -0.06 | -0.13 | -0.58 | -0.13 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | -- | -- | -- | -- |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | 1 | 1 | 1 | 1 |
Growth Estimates
| CURRENCY IN USD | CDTX | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | -333.30% | -- | -- | 1.50% |
| Next Qtr. | -42.90% | -- | -- | 11.40% |
| Current Year | -159.60% | -- | -- | 5.20% |
| Next Year | 100.70% | -- | -- | 13.40% |
| Next 5 Years (per annum) | 61.20% | -- | -- | 11.09% |
| Past 5 Years (per annum) | -- | -- | -- | -- |
Research Analysis
Upgrades & Downgrades
| Reiterates | Cantor Fitzgerald: Overweight | 4/23/2024 |
| Maintains | HC Wainwright & Co.: Buy to Buy | 4/8/2024 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 12/7/2023 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 11/6/2023 |
| Reiterates | Needham: Buy to Buy | 9/22/2023 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 9/22/2023 |
Related Tickers
ABEO Abeona Therapeutics Inc.
3.1100
-1.89%
TCON TRACON Pharmaceuticals, Inc.
1.9200
+1.59%
NRXP NRx Pharmaceuticals, Inc.
3.0800
-1.28%
EYEN Eyenovia, Inc.
0.6573
+12.61%
BPTH Bio-Path Holdings, Inc.
2.5500
+2.00%
IBRX ImmunityBio, Inc.
4.9288
+2.26%
ABVC ABVC BioPharma, Inc.
1.4650
-1.01%
NKGN NKGen Biotech, Inc.
2.0100
+17.65%
ASLN ASLAN Pharmaceuticals Limited
0.4770
+1.56%
ARDX Ardelyx, Inc.
6.26
-2.64%